Login to Your Account

Hospira Partner Celltrion Halts Trial for Biosimilar Rituxan

By Jennifer Boggs
Managing Editor

Friday, April 19, 2013

Celltrion Inc,. which scored a big win last year with the world's first officially approved biosimilar monoclonal antibody – Remsima, a biosimilar version of autoimmune blockbuster Remicade (infliximab, Johnson & Johnson) – has halted a late-stage trial testing a Rituxan/MabThera (rituximab) biosimilar.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription